FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Tuesday, May 13th. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Tuesday, April 1st.

FibroGen Trading Up 1.3%

FGEN stock opened at $0.31 on Friday. The company’s 50 day moving average is $0.32 and its 200 day moving average is $0.41. The stock has a market cap of $30.92 million, a price-to-earnings ratio of -0.25 and a beta of 0.86. FibroGen has a 1-year low of $0.18 and a 1-year high of $1.53.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.19). The firm had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts forecast that FibroGen will post -0.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director James A. Schoeneck acquired 250,000 shares of the stock in a transaction on Thursday, March 20th. The stock was acquired at an average cost of $0.35 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the director now directly owns 323,722 shares of the company’s stock, valued at approximately $113,302.70. This represents a 339.11% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thane Wettig bought 145,000 shares of FibroGen stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $0.35 per share, for a total transaction of $50,750.00. Following the acquisition, the chief executive officer now directly owns 543,329 shares in the company, valued at approximately $190,165.15. This trade represents a 36.40% increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.07% of the company’s stock.

Hedge Funds Weigh In On FibroGen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new stake in shares of FibroGen in the 4th quarter worth about $27,000. Velan Capital Investment Management LP bought a new stake in FibroGen during the fourth quarter worth about $42,000. XTX Topco Ltd grew its holdings in FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 77,693 shares during the period. HighTower Advisors LLC grew its holdings in FibroGen by 292.8% in the first quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 301,500 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of FibroGen during the fourth quarter valued at approximately $205,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.